Eckert & Ziegler Reports Strong Revenue and Earnings Growth in First Nine Months of 2022

Key Business Highlights

Eckert & Ziegler AG (ISIN: DE0005659700), a leading specialist in radiation therapy and nuclear medicine, has announced robust financial results for the first nine months of 2022. The company reported significant growth in both revenue and earnings, driven by strong demand for its products and services.

Revenue for the period from January to September 2022 amounted to EUR 239.4 million, reflecting an impressive 25.5% increase compared to the same period in 2021. This growth was predominantly driven by increased sales in the Radiation Therapy and Radiopharma segment.

In line with the revenue growth, Eckert & Ziegler also reported a notable increase in earnings. Earnings before interest and taxes (EBIT) for the first nine months of 2022 reached EUR 33.8 million, representing a substantial 35.6% increase compared to the previous year.

Segment Performance

Radiation Therapy and Radiopharma

The Radiation Therapy and Radiopharma segment, which contributes the majority of the company's revenue, continued its impressive growth trajectory. Revenue in this segment surged by 27.8% to EUR 186.7 million, primarily due to higher sales of brachytherapy products and services.

Brachytherapy is a type of radiation therapy that involves placing radioactive sources inside or near a tumor to deliver precise doses of radiation.

Medical

The Medical segment, which includes the production and distribution of radiopharmaceuticals and radioisotopes, also reported revenue growth of 15.3% to EUR 42.3 million. This growth was driven by increased demand for diagnostic and therapeutic radiopharmaceuticals.

Radioisotopes are used in various medical applications, including imaging and cancer treatment.

Industrial

The Industrial segment, which focuses on the production and distribution of products for industrial applications, saw a revenue increase of 12.4% to EUR 10.4 million. This growth was primarily fueled by increased sales of neutron sources used in industrial radiography and gauging.

Outlook

Eckert & Ziegler remains optimistic about its future prospects and expects continued growth in the coming quarters. The company plans to further expand its product portfolio and invest in research and development to maintain its competitive position.

The company's strong financial performance and positive outlook have been well-received by investors. Eckert & Ziegler's share price has risen significantly in recent months, reflecting the market's confidence in the company's long-term growth potential.